Nuclear medicine program progress report for quarter ending December 31, 1996
In this report the authors describe the use of an effective method for concentration of the rhenium-188 bolus and the results of the first Phase 1 clinical studies for bone pain palliation with rhenium-188 obtained from the tungsten-188/rhenium-188 generator. Initial studies with therapeutic levels of Re-188-HEDP at the Clinic for Nuclear Medicine at the University of Bonn, Germany, have demonstrated the expected good metastatic uptake of Re-188-HEDP in four patients who presented with skeletal metastases from disseminated prostatic cancer with good pain palliation and minimal marrow suppression. In addition, skeletal metastatic targeting of tracer doses of Re-188(V)-DMSA has been evaluated in several patients with metastases from prostatic cancer at the Department of Nuclear Medicine at the Canterbury and Kent Hospital in Canterbury, England. In this report the authors also describe further studies with the E-(R,R)-IQNP ligand developed in the ORNL Nuclear Medicine Program as a potential imaging agent for detection of changes which may occur in the cerebral muscarinic-cholinergic receptors (mAChR) in Alzheimer`s and other diseases.
- Research Organization:
- Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research, Washington, DC (United States)
- DOE Contract Number:
- AC05-96OR22464
- OSTI ID:
- 656448
- Report Number(s):
- ORNL/TM-13353; ON: DE98003638; TRN: AHC29817%%2
- Resource Relation:
- Other Information: PBD: 20 Mar 1997
- Country of Publication:
- United States
- Language:
- English
Similar Records
Bone marrow adsorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts
Nuclear medicine program progress report for quarter ending March 31, 1994